Diversified Financial articles

Agios Pharma Soaring 27% Pre-Bell; AG-221 Demonstrates Clinical Acitivity in Blood Cancer Patients

Agios Pharmaceuticals (AGIO) shares were up 27% in recent pre-market trade after saying this weekend that data from a study on the AG-221 drug in patients with advanced blood cancers showed “promising” clinical activity. AGIO is in the upper half of the 52-week range between $15.77 and $49.79. The purpose of the phase 1 program

Response Genetics Stock Jumps as Filing Shows Becker Drapkin Pared Stake

Response Genetics (RGDX) shares climbed in Monday’s pre-market session, after a late-Friday regulatory filing showed activist investor Becker Drapkin cut its stake last week in the developer of clinical diagnostic tests for cancer. RGDX was up 8.5% at $1.40 in recent pre-market trading, in a 52-week range of $1.09 to $2.93. The filing showed Becker

Top